Featured content
Why single-cell foundation models have underdelivered and what drug discovery needs instead
Foundation models have delivered breakthroughs in fields such as protein structure prediction, but single-cell biology presents different challenges. This article explores why scale alone is not enough and what kinds of AI may better support drug discovery.
ArticleGene therapy’s biggest challenge is the cell’s own defence mechanisms
What if one of gene therapy’s biggest obstacles isn’t delivery, but the body’s own cells? Discover why DNA silencing is emerging as a major challenge for long-lasting genetic medicines.
ArticleWhy inherited retinal disease treatment requires more than gene therapy
Most inherited retinal diseases still have no approved therapy despite advances in gene therapy. This article explores why researchers are targeting shared disease mechanisms alongside individual mutations.
ArticleUnderstanding the toxicology endpoints that matter in ADC development
Antibody-drug conjugates (ADCs) present unique toxicology challenges. Learn which endpoints matter most, how they inform development decisions and why they are essential for building a robust nonclinical safety strategy.
News
NewsAI designs functional bacteriophage genomes to overcome bacterial resistance
Scientists have used artificial intelligence to design complete, functional bacteriophage genomes from scratch, with engineered phages capable of overcoming resistance in bacteria that had defeated naturally occurring viruses — marking a significant step towards AI-driven whole-genome engineering.
NewsAI and genetics identify WNK2 inhibitor for osteoarthritis treatment
Researchers at University of Utah Health have used artificial intelligence and human genetic data to identify a promising early-stage drug candidate targeting WNK2, a protein linked to inherited osteoarthritis, with the lead compound reducing inflammatory gene activity and supporting cartilage cell health in laboratory models.
NewsNew molecular glue platform broadens E3 ligase targeting for cancer drug development
Researchers at Dana-Farber Cancer Institute have developed a scalable platform for discovering molecular glue degraders, reporting the first metabolically activated example and broadening the scope of targeted protein degradation in cancer.
NewsWhat Google’s AI talent exodus could mean for future drug discovery
The departure of leading AI researchers from Google to found Discovery Loop raises important questions about the future direction of artificial intelligence in scientific research and drug development.
From our partners
Article
Antibody recycling, FcRn and the next generation of biologics
One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the science behind FcRn and how researchers measure its function.
Article
Flow-based human tumour models reveal immune responses missed by static culture
Static cultures can miss critical immune–tumour interactions. Learn how the Mera™ flow-based human tissue model better captures T-cell activity to strengthen preclinical immunotherapy research.
Opinion and interviews
The global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
Meeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
Webinar
Building better therapeutic antibodies: the science, progress and problems to solve
As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
Webinar
Oligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics rapidly advance, their safety profile presents challenges unlike any other drug modality. Discover how nonclinical safety studies, regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
Meeting ethical & regulatory requirements when using human biological specimens
Building better therapeutic antibodies: the science, progress and problems to solve
Oligonucleotide therapeutics safety considerations across drug development
On-demand Webinars
- Previous
- Next
